Group B Streptococcus serotype Ib capsular polysaccharide-specific B cell receptor (GBS Ib BCR)

The Group B Streptococcus serotype Ib capsular polysaccharide-specific B cell receptor is a membrane-bound immunoglobulin complex on B lymphocytes that specifically recognizes the serotype Ib capsular polysaccharide (CPS) of Streptococcus agalactiae [1]. This receptor is a critical component of the adaptive immune system, mediating the recognition of GBS, which is a leading cause of neonatal sepsis, meningitis, and pneumonia worldwide [2]. Upon binding to its cognate antigen—typically delivered via a conjugate vaccine like the hexavalent GBS6—the receptor triggers intracellular signaling through the CD79a/b complex, leading to B cell activation and differentiation into plasma cells [3]. These plasma cells produce serotype-specific IgG antibodies that are essential for opsonophagocytic killing of the bacteria [4]. In the context of maternal immunization, the activation of these BCRs leads to the production of high-titer IgG that is transplacentally transferred to the fetus, providing passive protection to the neonate [5]. The receptor is thus the primary functional target for vaccines designed to prevent invasive GBS disease in infants [1, 2].

Other names

Group B Streptococcus type Ib capsular polysaccharide-specific B-cell receptorStreptococcus agalactiae serotype Ib CPS-specific BCRAnti-GBS Ib capsular polysaccharide B-cell receptor

Vaccines containing the GBS serotype Ib capsular polysaccharide bind to this specific B cell receptor, initiating a signaling cascade that leads to B cell activation, proliferation, and differentiation into plasma cells [3, 5]. These plasma cells produce serotype-specific IgG antibodies that opsonize the bacteria for phagocytic clearance [4].